Matrixx issuing coupons for oral products
This article was originally published in The Tan Sheet
In an effort to stay in business, Matrixx Initiatives expects to drive consumers to its Zicam oral cold remedies by using a "very large database" of customer information and distributing "high-value" coupons, according to Jim Marini, VP of sales. The Scottsdale, Ariz.-based firm looks to convert its customers to oral products following a June 16 voluntary recall of two homeopathic intranasal zinc-containing cold remedies after it received a warning letter from FDA that the products potentially cause anosmia, the loss of the sense of smell. FDA also told the firm to develop a plan to remove the affected Zicam products from the market (1"The Tan Sheet" June 29, 2009). At the National Association of Chain Drug Stores Marketplace trade show June 28 to July 1 in Boston, Marini said Matrixx is "informing retailers of our plans to grow our business" and of the firm's efforts to move consumers to alternative products. In an interview, Marini said Matrixx has received "overwhelming support" from its retailers
You may also be interested in...
Salvaging the Zicam brand by shifting consumers to its oral delivery products will be crucial to the survival of Matrixx Initiatives, as the firm's strategic options narrow in the wake of a major recall
DSHEA’s Scientific Literature Exemption is attracting attention for offering online studies showing nutrients’ benefits on diseases including COVID-19, though the method isn’t free of risks, suggests CRN executive Megan Olsen.
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.